Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer
Authors
Keywords
-
Journal
PROSTATE
Volume 75, Issue 9, Pages 923-935
Publisher
Wiley
Online
2015-03-19
DOI
10.1002/pros.22976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- C-Kit and Its Ligand Stem Cell Factor: Potential Contribution to Prostate Cancer Bone Metastasis
- (2015) Christoph Wiesner et al. NEOPLASIA
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Estrogenic regulation of testicular expression of stem cell factor and c-kit: implications in germ cell survival and male fertility
- (2014) Sara Correia et al. FERTILITY AND STERILITY
- Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
- (2014) Barbara Kahn et al. International Journal of Biological Sciences
- Bone-induced c-kit expression in prostate cancer: A driver of intraosseous tumor growth
- (2014) Leandro E. Mainetti et al. INTERNATIONAL JOURNAL OF CANCER
- The SCF/c-KIT system in the male: Survival strategies in fertility and cancer
- (2014) Henrique J. Cardoso et al. MOLECULAR REPRODUCTION AND DEVELOPMENT
- Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner
- (2014) Roberta M. Moretti et al. PLoS One
- Transgenic overexpression of regucalcin leads to suppression of thapsigargin- and actinomycin D-induced apoptosis in the testis by modulation of apoptotic pathways
- (2014) S. Correia et al. Andrology
- Androgens and prostate cancer; pathogenesis and deprivation therapy
- (2013) Mathis Grossmann et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting caspases in cancer therapeutics
- (2013) Patrick Hensley et al. BIOLOGICAL CHEMISTRY
- c-kit expression profile and regulatory factors during spermatogonial stem cell differentiation
- (2013) Lei Zhang et al. BMC DEVELOPMENTAL BIOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
- (2013) Alia Ahmed et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
- (2012) C Nabhan et al. BRITISH JOURNAL OF CANCER
- Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile
- (2012) Cátia V. Vaz et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
- (2012) Colin Brooks et al. Radiation Oncology
- PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells
- (2011) Yoshihiko Kadowaki et al. APOPTOSIS
- Proliferative versus apoptotic functions of caspase-8
- (2011) Bram J. van Raam et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling
- (2011) Lu Gan et al. PROSTATE
- Phase I Trial of Zoledronic Acid + Imatinib Mesylate (Gleevec) in Patients With Bone Metastases
- (2010) Allan Lipton et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy
- (2010) Ana Catarina Pinto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Caspase-8 as a therapeutic target in cancer
- (2010) Dwayne G. Stupack CANCER LETTERS
- Imatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial Hypertension
- (2010) Masaru Hatano et al. International Heart Journal
- VEGF Inhibitors and Prostate Cancer Therapy
- (2010) Jeanny Aragon-Ching et al. Current Molecular Pharmacology
- p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells
- (2009) Nuria Ferrandiz et al. CANCER LETTERS
- Regucalcin is under-expressed in human breast and prostate cancers: Effect of sex steroid hormones
- (2009) Cláudio Maia et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
- (2009) A. Choudhury et al. MOLECULAR CANCER THERAPEUTICS
- The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer
- (2008) Sheng-Qiang Yu et al. ASIAN JOURNAL OF ANDROLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor is a tumor suppressor and proliferator in prostate cancer
- (2008) Y. Niu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?
- (2008) Jerry E. Chipuk et al. TRENDS IN CELL BIOLOGY
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started